Trials / Completed
CompletedNCT06677138
PK Study of Gefurulimab SC in Healthy Chinese Adult Participants
A Phase 1 Study to Evaluate the Pharmacokinetics, Pharmacodynamics, Safety, and Immunogenicity of Gefurulimab (ALXN1720) in Healthy Chinese Adults
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 8 (actual)
- Sponsor
- Alexion Pharmaceuticals, Inc. · Industry
- Sex
- All
- Age
- 18 Years – 45 Years
- Healthy volunteers
- Accepted
Summary
The primary objective of this study is to characterize the PK properties of a single dose of gefurulimab in healthy Chinese participants.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | gefurulimab | Participants will receive gefurulimab subcutaneously (SC). |
Timeline
- Start date
- 2024-10-28
- Primary completion
- 2025-03-19
- Completion
- 2025-03-19
- First posted
- 2024-11-06
- Last updated
- 2025-05-01
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT06677138. Inclusion in this directory is not an endorsement.